Waltham, MA-based Quantia has reeled in $10 million for a Series B round of funding, led by Safeguard Scientifics.
The U.K. biotech Acacia Pharma has won the embrace of some top-shelf venture players willing to step in to fund a late-stage study of its lead drug.
Venture firms have traveled a variety of new routes to limit risks and score returns in biotech, and the Wall Street Journal has covered how Clarus Ventures and OrbiMed Advisors have found potentially lucrative ways of investing in the pipelines of established pharma companies.
Icon Bioscience has scored $14.9 million in a Series B round of financing, according to an SEC filing on Wednesday. The funding comes as the California drug developer advances a lead therapy for patients after cataract surgeries in late-stage development.
Sofinnova Ventures and Novo A/S led a $34.5 million Series A round for ObsEva, a Geneva-based biotech that is snatching up Merck Serono's preterm labor drug program and pushing ahead on the development front. And MS Ventures, the Big Pharma's VC arm, is taking an equity stake in the biotech company in exchange for the worldwide rights.
In a gamble on making oral version of typically injected therapies, Google Ventures has joined forces with InCube Ventures and VentureHealth to fund a Series B round for Rani Therapeutics. And with its lofty oral-delivery goals, San Jose, CA-based Rani is tackling the kind of big idea in biotech that Google's venture fund likes to bankroll.
There's been a considerable amount of moaning and groaning in recent years over the clear lack of capital needed to start up a biotech. But Third Rock Ventures has helped banish the blues in certain quarters.
Waltham, MA-based Syndax Pharmaceuticals took a big step to the threshold of a key pivotal study for its lead cancer therapy today, completing a $26.6 million venture round. The funds will pay for a Phase III study of entinostat, an HDAC inhibitor which promises to extend the efficacy of a standard breast cancer therapy.
With a Phase III cancer immunotherapy study under way, Durham, NC-based Argos Therapeutics today put in place its fifth fundraising, banking $42.5 million from a big group of backers led by a pair of unorthodox players.
Few people in the U.K.'s biotech industry have as much influence as Chris Evans. That influence was on full display this week after the high-flying investor took a personal, million-dollar stake in the regenerative medicine company ReNeuron, which is being refinanced and moved to Wales as part of a Welsh government effort to build a biotech hub in the region.